Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

To evaluate the efficacy and safety of combination of anticoagulant and antiplatelet therapy on the patency of iliac vein at 12-month post stenting in patients with acute proximal DVT and ipsilateral iliac vein stenosis who received percutaneous mechanic thrombectomy and iliac vein stenting.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• IC1. Subjects who were diagnosed with deep venous thrombus (DVT) with ipsilateral iliac venous stenosis (\>50%). The ipsilateral iliac venous stenosis can be caused either by iliac vein compression (i.e. Cockett syndrome) or residue iliac venous thrombus after percutaneous mechanic thrombectomy.

• IC2. Subjects who accepted percutaneous mechanic thrombectomy (PMT) to decrease the burden of thrombus, with or without catheter directed thrombolysis (CDT).

• IC3. Subjects who accepted iliac venous stent(s) implantation during the perioperative period of PMT or CDT (≤30 days post PMT or CDT) .

Locations
Other Locations
China
The First Affliated Hospital, Zhejiang University, School of Medicine
RECRUITING
Hangzhou
Contact Information
Primary
Hongkun Zhang, M.D.
1198050@zju.edu.cn
0571-87236745
Time Frame
Start Date: 2021-11-03
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 172
Treatments
Experimental: Anticoagulant plus antiplatelet therapy
For anticoagulant, it is rivaroxaban 20mg once a day for 6 months. For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
Sponsors
Collaborators: Taizhou Enze Medical Center Group, Boston Scientific Corporation, Zhejiang University, Ningbo No.2 Hospital, Taizhou First People's Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City
Leads: First Affiliated Hospital of Zhejiang University

This content was sourced from clinicaltrials.gov